Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XM 02 vs Filgrastim in breast cancer patients receiving chemotherapy
2004-001452-36Phase 3Completed
- Sponsor
- BioGeneriX AG
- Start
- Aug 2004
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of tbo-filgrastim in breast cancer and chemotherapy-induced neutropenia (CIN) (2 arms), sponsored by BioGeneriX AG. Primary endpoint: Duration of severe neutropenia in first chemotherapy cycle. Started Aug 2004; status: completed.
02
Drugs
tbo-filgrastim
03
Conditions
breast cancerchemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on 2004-001452-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001452-36.